Research Article

iMedPub Journals
http://www.imedpub.com

Journal of Infectious Disease and Treatment
ISSN:2472-1093

2021
Vol. 7 No. 7: 51

DOI: 10.36648/2472-1093.7.7.51

An Overview of Coronavirus (Covid-19) drugs and recent status of vaccine trials

Cameliya Sinha Roy, Ayan Raichaudhuri

Amity Institute of Biotechnology, Amity University, New Town, Kolkata 700135, India, E-mail: cameliyasingharoy@gmail.com

Corresponding author: **Ayan Raichaudhuri** *, Address: Amity Institute of Biotechnology, Amity University, New Town, Kolkata 700135, Telephone: +91 9433073732,

Email: araichaudhuri@kol.amity.edu, ayan123@gmail.com

Received Date: May 21, 2021 **Accepted Date:** June 01, 2021, **Published Date:** June 22, 2021

Citation: Cameliya Sinha Roy, "An Overview of Coronavirus (Covid-19) drugs and recent status of vaccine trials" J Infec Dis Treat, Vol.7 No.1:51

Abstract

A flare-up identified with the serious intense respiratory disorder coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An incredibly high potential for scattering came about in the worldwide coronavirus illness 2019 (COVID-19) pandemic in 2020. Regardless of the exacerbating patterns of COVID-19, no medications are approved to have huge viability in the clinical treatment of COVID-19 patients in enormous scope examines. Remdesivir is viewed as the most encouraging antiviral operator; it works by repressing the movement of RNA-subordinate RNA polymerase (RdRp). The other superb enemy of flu RdRp inhibitor favipiravir is likewise being clinically assessed for its adequacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone isn't appeared to give preferable antiviral adequacy over standard consideration. Another promising option is hydroxychloroquine (200 mg threefold day by day) in addition to azithromycin (500 mg on day 1, trailed by 250 mg once every day on day 2-5), which indicated fantastic clinical adequacy on Chinese COVID-19 patients and hostile to SARS-CoV-2 intensity in vitro. The jobs of teicoplanin (which hinders the viral genome introduction in the cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under scrutiny. Staying away from the remedy of non-steroidal calming drugs, angiotensin changing over protein inhibitors, or angiotensin II type I receptor blockers is exhorted for COVID-19 patients. The vaccines, the most important stage for the relief from COVID-19 is under various trials.

Keywords:

COVID-19, SARS-CoV-2, reverse-transcription polymerase chain reaction, false positive

Introduction

An unexpected pandemic is making the entire world to endure by a novel cold sickness. The flare-up was first announced in Wuhan, China in December 2019. On the primary spot, it was thought as a novel strain of crown infection [83], which was named as 2019-nCoV by the World Health Organization (WHO) [84] [85][86]. Later the International Committee on Taxonomy of Viruses renamed it as SARS-CoV-2. The pandemic illness brought about by the SARS-CoV-2 was named as Coronavirus ailment 2019 (Covid-19) by WHO. It is an RNA virus, having a diameter of 60 nm to 140 nm. It has got a spike-like surface projection. As it is found under electron microscope surveillance, it seems like a crown-shaped virus so named accordingly as coronavirus [92]. Up until now, four such crown infections specifically HKU1, NL63, 229E, and OC43 causing mellow respiratory ailment have been available for people.

As announced, there have been two such events in the previous two decades with the hybrid of creature beta crown infections to people, brought about the extreme malady. The primary occasion was accounted for in 2002–2003 when another coronavirus of the β genera with beginning in bats ignored to people through delegate host of palm civet felines in the Guangdong territory of China. This infection, have caused the serious intense respiratory condition and influenced 8422 individuals (generally in China and Hong Kong) coming about 916 passing (death rate 11%) before being contained [90]. Again in 2012, the Middle East respiratory condition coronavirus (MERS-CoV), again of bat source, brought up in Saudi Arabia with dromedary camels as the moderate host, influenced 2494 individuals and detailed 858 passings (casualty rate 34%) [91]. There is a use of a few drugs like Remdesivir, Favipiravir, etc, yet the actual treatment is not yet discovered. The ultimate reliance is upon the vaccine development for the same. And hence the process of vaccine development is still under trial process.

Remdesivir:

There are many potential drugs, that are being tested for the efficacy in the treatment of the SARS-CoV-2 infection [2]. Among these Remdesivir(GS-5734; Gilead Sciences Inc., Foster City, CA, USA) has shown the most promising result as an anti-viral therapeutic. This drug targets the viral- RNA-dependent RNA polymerase (RdRp), while evading the proofreading by viral exoribonuclease [3]. This results in prematurely terminating the viral RNA transcription. Remdesivir is a phosphoramidite pro-drug with broad-spectrum against many virus families (like Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae {such as pathogenic SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]}) [4][5].

But still, the pharmacokinetics of the drug remdesivir in humans is yet to be known. Though, the data is obtained from the rhesus monkeys, it showed an intravenous dose of 10 mg/kg. That leads to a remarkable high intracellular concentration (>10 μM) of active triphosphate form in peripheral blood mononuclear cells for at least of 24 hours [6]. This supports its clinical potentiality in treating human SARS-CoV-2 infection and also the data of remdesivir safety is now available online [7]. On January 2020 remdesivir treated the first COVID-19 patient of USA for the progression of pneumonia on the 7th day of hospitalization [1]. Since March 2020, remdesivir has gone for phase 3 human trials (ClinicalTrials.gov Identifier: NCT04292899 and NCT04292730, for severe and moderate adult SARS-CoV-2 cases, respectively) to evaluate its efficiency in affected humans with SARS-CoV-2 infection. Patients were given 200 mg on 1st day, followed by 100mg/ day from day 2. It has got encouragingly high in vitro potency against the infection and also got success in COVID-19 as well [1], [14].Still, there are adverse effects (e.g., nausea, vomiting, rectal hemorrhage, and hepatic toxicity), that are reported recently [8].

Tests have been done on a mouse model for investigating the pathogenesis of SARS-CoV.The prophylactic and early therapeutic post-exposure administration of the remdesivir drug has shown to produce a significant reduction in the pulmonary viral load (i.e., >2 orders of magnitude on day 2–5 post-infection). It can also mitigate disease progression and prominently improve respiration function [40]. Also, it has been observed that remdesivir display half-maximum effective concentrations (EC50s) of 0.069 μM for SARS-CoV, and 0.074 μM for MERS-CoV in the tissue culture models [9].

The tissue lifestyle experiments additionally have proven that many fantastically divergent CoV, which incorporates the endemic human CoVs (HCoV-OC43, HCoV-229E) and zoonotic CoV. These are successfully inhibited with the aid of using remdesivir in the submicromolar EC50s [9] [10]. The same efficacy of prophylactic and healing remdesivir treatment (24 h previous to inoculation, and 12 h post-inoculation, respectively) changed into additionally visible with the context of a non-human primate (rhesus macaque) version of MERS-CoV infection [11]. Although amino acid substitutions (F476L, V553L) with the non-structural protein 12 polymerases had been confirmed to confer low-stage resistance to remdesivir, this resistance additionally impaired the health of the examined CoVs and is in reality hard to select [3].

Favipiravir:

Another RdRp inhibitor favipiravir (Fujifilm Toyama Chemical Co. Ltd, Tokyo, Japan) is known to be dynamic in vitro against oseltamivir-safe flu A, B, and C viruses [87]. After being changed over into a functioning phosphoribosylated structure, favipiravir is effectively perceived as a substrate of viral RNA polymerase in numerous RNA viruses [88]. The suggested portion of favipiravir against flu infection is 1600 mg managed orally every day on day 1. At that point 600 mg twice daily on day 2–5 and 600 mg once on day 6. As of late, starter consequences of clinical investigations have demonstrated favipiravir to have promising strength in the treatment of Chinese patients with SARS-CoV-2 infection [89]. Favipiravir was endorsed for the treatment of COVID-19 in China in March 2020. Also, patients with COVID-19 disease are being enlisted for randomized preliminaries to assess the adequacy of favipiravir in addition to interferon-α (ChiCTR2000029600) and favipiravir in addition to baloxavirmarboxil (ChiCTR2000029544).

Ribavirin:

Ribavirin (Bausch Health Companies Inc., Bridgewater, NJ, USA), is a guanosine analog antiviral drug. It has been used to deal with numerous viral infections, consisting of the hepatitis C virus, respiratory syncytial virus (RSV), and a few viral hemorrhagic fevers. The in vitro antiviral activity of ribavirin in opposition to SARS-CoV becomes anticipated to be at the attention of 50 μg/mL [12]. However, it has the unwanted destructive impact of decreasing hemoglobin, which is dangerous for sufferers in respiratory problems [5].

Interferons:

Treatment with interferon β (IFNb)-1b (Bayer Pharmaceutical Co., Leverkusen, Germany), an immunomodulatory agent, becomes proven to bring about scientific development amongst MERS-CoV-inflamed not unusual place marmosets. However, the advantages of IFNb-1b for SARS sufferers stay uncertain[12][13].

Lopinavir/Ritonavir:

Protease inhibitors (PIs) are vital sellers with inside the cutting edge remedy of sufferers with continual human immunodeficiency virus (HIV) contamination. Concerning the Orthocoronavirinae family, the real objectives of PIs are papain-like protease and 3C-like protease [13]. The antiviral activity of lopinavir (LPV; Abbott Laboratories, Lake Bluff, Illinois, US) towards MERS-CoV in a tissue lifestyle version is controversial. Nevertheless a very good impact in mitigating sickness development in MERS-CoV-inflamed marmosets [12]. Of note, as compared the efficacy of prophylactic remdesivir (25 mg/kg two times a day, administered 1 day previous to contamination) in addition to healing remdesivir with that of LPV/ritonavir (RTV, used to lengthen the LPV's half-life)-IFNb aggregate remedy in a humanized transgenic mouse MERS-CoV contamination version. They located the efficacy of remdesivir became advanced to that of LPV/RTV-IFNb towards MERS-CoV in phrases of viral load discount and development in volume of pathologic extrade in lung tissue [14]. In addition to gastrointestinal unfavorable effects (nausea, vomiting, and diarrhea) brought on through LPV/RTV, it's miles noteworthy that LPV/RTV remedy alone (400/one hundred mg administered orally two times every day for 14 days; Chinese Clinical Trial Register range, ChiCTR2000029308) didn't offer blessings as compared to traditional care alone. The median time to scientific development in each instance became sixteen days (chance ratio [HR], 1.31; ninety-five % self-belief interval [CI], 0.ninety five to 1.85; P = 0.09) and there has been no distinction with inside the discount of viral RNA loading for excessive SARS-CoV-2 sufferers [15].

Despite discouraging results, it's miles fascinating that a barely decrease range of deaths became located inside the organization receiving LPV/RTV with inside the overdue degree of SARS-CoV-2 contamination as compared with the standard-care organization. Moreover, it has been observed that the LPV/RTV attention vital to inhibit pulmonary SARS-CoV-2 replication is probably better than the serum level [14][16]. A randomized managed open-label trial became released in China to assess the efficacy of LPV/RTV (200/50 mg two times a day) amongst hospitalized sufferers with SARS-CoV-2 infections in 2020 (ChiCTR2000029308). The position of darunavir (Janssen Pharmaceutica, Beerse, Belgium), additionally a promising PI towards SARS-CoV-2 in vitro, desires to be similarly evaluated [17]. Ribavirin in aggregate with interferon-α 2b became proven to be lively towards MERS-CoV in a rhesus macaque version[18]. Additionally, the routine of LPV/RTV plus ribavirin became proven to be powerful towards SARS-CoV in sufferers and tissue lifestyle[19].

Chloroquine:

It is energetic towards malaria in addition to autoimmune diseases (including rheumatoid arthritis [RA], lupus erythematosus). It changed into lately stated as a capacity broad-spectrum antiviral drug for remedy of viruses including influenza H5N1 in an animal model [20]. Chloroquine changed into proven to growth endosomal pH, which prevents virus/cellular fusion. It additionally interferes with the glycosylation of cell receptors of SARS-CoV [21, 22]. Although the in vitro facts of chloroquine is promising (EC90 of 6.90 μM, the use of Vero E6 cells inflamed with the aid of using SARS-CoV-2), an in-depth prescription of chloroquine in the medical remedy of SARS-CoV-2 is an off-label use. It isn't supported in slight of protection concerns (destructive results at the hematologic, hepatic and renal systems, QTc prolongation with ventricular dysrhythmia) and could in all likelihood bring about a chief scarcity of anti-malarial armamentaria [23].

Hydroxychloroquine:

It is likewise proposed to manipulate the cytokine hurricane, which takes place in seriousl SARS-CoV-2 sufferer. Hydroxychloroquine is considerably stronger than chloroquine in vitro (EC50 values: 0.72 and 5.47μM, respectively) and has a decreased capacity for drug-drug interactions than chloroquine. Pharmacokinetic fashions display that hydroxychloroquine sulfate is a huge superior (5 days in advance) to chloroquine phosphate in inhibiting SARS-CoV-2 in vitro [24]. The Taiwan CDC declared hydroxychloroquine as a crucial anti-SARS-CoV-2 agent on 26 March 2020. Of note, sufferers with retinopathy, deficiency of glucose-6-phosphatase, QTc prolongation in electrocardiograms, records of an allergic reaction to hydroxychloroquine, or who're pregnant or breastfeeding are contraindicated for receiving hydroxychloroquine therapy [25].

Azithromycin:

It (Pfizer Inc., Manhattan, New York City, NY, USA) changed into proven to be energetic in vitro towards Ebola viruses [26]. Furthermore, azithromycin is a concept to have the proper capacity in stopping intense breathing tract infections amongst pre-college kids whilst it is far administrated to sufferers struggling viral contamination [27]. According to a current study, azithromycin (500 mg on day 1, observed with the aid of using 250 mg in keeping with the day on day 2–5) changed into proven to noticeably enhance the efficacy of hydroxychloroquine with the remedy of 20 sufferers with intense COVID-19. Mean serum hydroxychloroquine attention changed into 0.46 ± 0.20 μg/mL. The properly medical final results amongst those COVID-19 sufferers changed into a concept to be because of the first-rate performance of virus removal after the management of this mixture therapy [25]. Consequently, the routine of hydroxychloroquine in mixture with azithromycin is probably a promising opportunity to remdesivir within the remedy of sufferers with SARS-CoV-2 contamination inside the future. Nevertheless, the opportunity of complex QTc prolongation ought to be concerned.

Teicoplanin and other glycopeptides:

The different antibiotics well worth citing on this assessment are glycopeptides. Teicoplanin (Sanofi Pharmaceuticals, Paris, France) turned into established to potently save you the access of Ebola envelope pseudotyped viruses into the cytoplasm.Additionally it has an inhibitory impact on transcription-in addition to replication-ready virus-like debris with inside the low micromolar range (IC50 330 nM). Moreover, teicoplanin is capable to block the MERS and SARS envelope pseudotyped viruses as nicely [28]. Mechanistic investigations found out that teicoplanin in particular inhibits the sports of host molecular's cathepsin L and cathepsin B. Teicoplanin cleaves the viral glycoprotein permitting publicity of the receptor-binding area of its center genome and next launch into the cytoplasm of host cells [29, 30]. Thus, it blocks Ebola virus access inside the overdue endosomal pathway. This research implies the capacity function of teicoplanin and its derivatives (dalbavancin, oritavancin, and telavancin) as novel inhibitors of cathepsin L-based viruses.

Ivermectin:

Ivermectin is an antiparasitic drug, classically prescribed at our dermatologic health center as a first-line remedy for cutaneous larva migrans. Interestingly, it additionally displayed an antiviral hobby. Indeed, ivermectin acts as a selected inhibitor of importin-α/β–mediated nuclear import. Thus, via way of means of impacting on importin-α/β–based nuclear shipping of viral proteins, ivermectin suppresses the replication of numerous RNA viruses, consisting of HIV, chikungunya virus, and yellow fever virus [64].

Melatonin:

When thinking about using melatonin to deal with COVID-19, the protection of the melatonin is of maximum importance to consider. As reviewed previously, short-time period use of melatonin is secure, even in the ones given excessive doses, and the said destructive outcomes are constrained to occasional dizziness, headache, nausea, and sleepiness; in trendy melatonin's protection in people could be very excessive [57]. In scientific trials, doses of 3 mg, 6 mg, and 10 mg of melatonin oral consumption via way of means of sufferers in ICU confirmed the best protection while in comparison to placebo [56,58,59]. Also, even if melatonin turned into a given to people at a dose of 1 g/d for a month, there have been no destructive reviews of the remedy [60]. Finally, there have been no destructive outcomes recorded after using melatonin in ALI/ARDS animal research [61,62,63]. While the protection of melatonin has been validated in lots of human research, its impact while given to COVID-19 sufferers have to be cautiously monitored despite the very excessive protection profile of melatonin.

Monoclonal or polyclonal antibodies and different therapies:

Monoclonal or polyclonal antibodies were recommended as prophylactic and healing tools (focused on hemagglutinin binding) towards a few viral infections, consisting of influenza [31]. Current efforts in growing monoclonal and polyclonal antibodies towards coronaviruses especially goal MERS-CoV [18]. For example, a human polyclonal antibody SAB-301 (50 mg/kg) that turned into generated in transchromosomic livestock turned into located to be nicely tolerated and secure in wholesome contributors of section 1 scientific trial [32]. However, [Cockrell et al. (2016)] located that immune-primarily based remedy with human monoclonal antibodies best-supplied safety towards early degree sickness resulting from MERS-CoV in mouse models [19, 33].

Numerous in vitro research has proven that the spike protein of SARS-CoV is critical in mediating viral access into goal cells. Furthermore, the cleavage and next activation of the SARS-CoV spike protein via way of means of a protease of the host mobileular is surely important for infectious viral access [34]. Type II transmembrane serine protease TMPRSS2 turned into recommended to be a critical host protease that cleaves and turns on the SARS-CoV spike protein in mobileular cultures and turned into hence explored as a capacity antiviral agent [18]. In a decade, the serine protease inhibitor camostatmesylate turned into proven to inhibit the enzymatic hobby of TMPRSS2 [35]. Additionally, the cysteine PI K11777 confirmed promising efficiency in inhibiting MERS-CoV and SARS-CoV replication with inside the submicromolar range [36].

The use of stem cells towards COVID-19 has been below the assessment in China recently. Additionally, tocilizumab (Roche Pharmaceuticals, Basel, Switzerland) is a monoclonal antibody this is used with inside the remedy of RA exacerbation. It turned into designed to inhibit the binding of interleukin-6 to its receptors, hence assuaging cytokine launch syndrome. Currently, it's also being investigated for the remedy of COVID-19 [37].

Convalescent plasma:

Convalescent plasma has additionally been used as an ultimate lodge to enhance the survival fee of sufferers with numerous viral infections. It consists of SARS, H5N1 avian influenza, pandemic 2009 influenza A H1N1 (H1N1 pdm09), and extreme Ebola virus contamination [38, 39]. One feasible cause of the efficacy of convalescent plasma remedy is that the immunoglobulin antibodies with inside the plasma of sufferers recuperating from viral contamination would possibly suppress viremia. The convalescent plasma received from five sufferers who recovered from COVID-19 and is administered to the 5 enrolled sufferers among 10 and 22 days after admission. Antiviral retailers and methylprednisolone have been additionally administered. Following plasma transfusions, enhancements in scientific circumstances have been located, consisting of normalization of frame temperature inside three days (in 4/5 sufferers), lower in Sequential Organ Failure Assessment score, upward thrust in PaO2/FiO2, the decision of ARDS (four sufferers at 12 days after transfusion). A fulfillment of weaning from mechanical ventilation (three sufferers inside 2 weeks of remedy), and decline in viral loads (have become poor inside 12 days) and growth in SARS-CoV-2–unique ELISA and neutralizing antibody titers. Of the five sufferers, three have been discharged from the hospital (lengths of stay: 53, 51, and 55 days) even as 2 have been in a strong circumstance at 37 days after transfusions [39]. The authors concluded that the use of convalescent plasma transfusion is useful amongst sufferers inflamed with SARS-CoV-2, even though the pattern range on this observe is small [39].

Herbal medications:

Based on the ancient data and anecdotal proof of SARS and H1N1 pdm09 prevention, Chinese natural pills have been additionally taken into consideration as an opportunity method for the prevention of COVID-19 in excessive-hazard populations. However, scientific proof for those remedies with inside the prevention of this rising viral contamination is lacking [40, 41]. During the COVID-19 outbreak in China, a few conventional Chinese remedies turned into extensively used and the six maximum generally used natural drug treatments have been Astragali Radix (Huangqi), Glycyrrhizae Radix Et Rhizoma (Gancao), Saposhnikoviae Radix (Fangfeng), Atractylodis Macrocephalae Rhizoma (Baizhu), Lonicerae Japonicae Flos and Fructus forsythia (Lianqiao). However, rigorous scientific trials on big populations have to be carried out to verify the capacity preventive impact of Chinese remedy [40, 41].

Antimicrobial retailers for capacity co-contamination:

The occurrence of co-contamination various amongst COVID-19 sufferers, starting from 0% to 50% amongst non-survivors. Reported co-pathogens covered bacteria, consisting of Mycoplasma pneumoniae, Candida species, and viruses (influenza, rhinovirus, coronavirus, and HIV). Influenza A virus turned into the most typical co-infective virus [42]. Co-management of anti-influenza retailers and anti-bacterial retailers in sufferers with COVID-19 pneumonia turned into common [42]. Consequently, a careful prescription of powerful antibiotic(s) masking Staphylococcus aureus (consisting of methicillin-resistant S. Aureus), multidrug-resistant Streptococcus pneumonia, Klebsiella pneumoniae, and Pseudomonas aeruginosa in addition to Acinetobacter baumannii species for sufferers present process lengthy hospitalization (>6 days) is advised [43, 44].

Based on the studies [45], the maximum one-of-a-kind comorbidities **a** few of the non-survivors of COVID-19 in depth care devices have been cerebrovascular sickness and diabetes. Similar findings have been additionally located via way of means of [63]; those sufferers have been typically dealt with ACE inhibitors or angiotensin II kind I receptor blockers (ARB). As stated above [5], [12], SARS-CoV-2 and SARS-CoV can bind to their goal cells via ACE2 receptors expressed via way of means of the epithelial cells of the lung, gut, and kidney [47]. Consequently, cautious management of an ACE inhibitor or ARB for sufferers with SARS-CoV contamination with inside the absence of ARDS is advised.

Additionally, despite conflicting recommendations from the United States Food and Drug Administration [48], using non-steroidal anti-inflammatory pills (NSAIDs), consisting of ibuprofen, turned into a notion to be probably to bring about the induction of accelerated ACE2 receptors [49]. For significantly sick adults with COVID-19 who broaden fever, acetaminophen is probably a higher desire for temperature manages than NSAIDs [50]. Of note, consistent with an observation, the remedy of COVID-19 sufferers with methylprednisolone turned into proven to lower the case-fatality hazard (HR, 0.38; 95% CI, 0.20–0.72) [51]. However, the administered dose of methylprednisolone isn't always laid out in that investigation. Despite a loss of helping proof, a few important care professionals advise using low-dose corticosteroid remedy in adults with COVID-19 and refractory shock (e.g., intravenous hydrocortisone 200 mg in line with day, as a "shock-reversal" strategy) [51]. Moreover, the latest document established that anticoagulant remedy with heparin (especially with low molecular weight heparin) turned into related to higher diagnosis in extreme COVID-19 sufferers. The 28-day mortality of heparin customers turned into decrease than that of non-customers amongst sufferers with sepsis-brought about coagulopathy scores ≥four (40.0% vs. 64.2%, P = 0.029), or D-dimer > 6-fold the higher restrict of normal (32.8% vs. 52.4 %, P = 0.017) [52].

Finally, excessive ACE2 hobby is related to decreased severity of ARDS amongst sufferers with decrease respiration tract contamination resulting from RSV [53]. Fedson et al. (2016, 2020) located that statins goal the host reaction to contamination (endothelial dysfunction) in preference to the virus itself, and recommended that mixture remedy with ARB and statins would possibly boost up a go back to homeostasis, permitting sufferers to get better on their own [54, 55].

Vaccines:

The S protein is the most important goal for COVID-19 vaccine improvement, especially primarily based totally on the elicitation of virus-neutralizing antibodies because the immune correlates to vaccine safety. The modern repute of COVID-19 vaccine improvement includes, i) 3 section I vaccine applicants, ii) eleven preclinical vaccine applicants, and iii) 26 studies degree vaccine applicants (Table 1; [81]). Most of those vaccine applicants are primarily based totally at the S antigen both as inactivated vaccines, subunit vaccines, viral vectored vaccines, and nucleic acid primarily based DNA or mRNA vaccines. Among those vaccine applicants, the Coalition for Epidemic Preparedness Innovations (CEPI) has supplied investment to broaden COVID-19 vaccines the usage of the subsequent platform technology: a) Curevac Inc. (mRNA), b) Inovio Pharmaceuticals Inc. (DNA), c) Moderna, Inc. (mRNA), d) University of Queensland (molecular clam), e) Novavax (nanoparticles), f) University of Oxford (adenovirus vector), g) University of Hong Kong (live attenuated influenza virus), and h) Institute of Pasteur (measles vector) to boost up the improvement of vaccines and permit equitable get admission to those vaccines for human beings in the course of outbreaks [93]. Table 1:

Company	Vaccine candidates	Status
Moderna	mRNA1273	Phase 2
NCT04283461		
CanSino Biologics	Ad5-nCoV	Phase 2
ChiCTR2000030906		
Inovio	INO-4800 (DNA)	Phase I
NCT04336410		
Pfizer and BioNTech	BNT162 (mRNA)	Pre-clinical
Novavax	Recombinant nanoparticle vaccine	Phase 1
Curevac	Mrna-based vaccine	Phase 1
Generex	Ii-Key peptide vaccine	Pre-clinical
Vaxart	Oral recombinant vaccine	Pre-clinical
Imperial college london	Self-amplifying rna vaccine	Pre-clinical
Medicago	Plant-based vaccine (VLP)	Pre-clinical
Takis biotech	DNA-based vaccine	Pre-clinical
J&J and BARDA	Advac and PER.C6 systems	Pre-clinical
Altimmune	Intranasal vaccine	Pre-clinical
University of Saskatchewan	Protein subunit vaccine	Pre-clinical
Clover and GSK	S-Trimer	Pre-clinical
Heat biologics	Gp96-based vaccine	Research
CSL and University of Queensland	Molecular clamp vaccine	Research
Sanofi	Not revealed	Research
Ibio	Plant-based vaccine	Research
Expres2ion Biotechnologies	Not revealed	Research
Epivax	Ii-Key peptide vaccine	Research
Codagenix	Live attenuated vaccine	Research
Zyduscadila	DNA and/or live attenuated recombinant vaccine candidate	Research
Sinovac	CoronaVac	Phase 3
Geovax and Bravovax	Modified Vaccinia Ankara virus like particles (MVA-VLP) vaccine	Research
University of Oxford	Chimpanzee adenovirus vaccine vector (ChAdOx1)	Phase 3
Greffex	Adenovirus-based vector vaccine	Research
Walter Reed and USAMARIID	Not revealed	Research
MIGAL	Modified avian coronavirus vaccine	Research
Vaxil Bio	Protein subunit COVID-19 vaccine candidate	Research
AJVaccines	Not revealed	Research
Baylor	Re-purposed SARS vaccine;	
S1 or RBD protein vaccine	Research	
Institut Pasteur	Not revealed	Research
Tonix Pharmaceuticals and Southern Research	Horsepox vaccine with percutaneous administration	Research
Fudan University, Shanghai Jiao Tong University, and RNACureBiopharma	mRNA-based vaccine	Research
Arcturus Therapeutics and Duke-NUS	Self-replicating RNA and nanoparticle non-viral delivery system	Research
University of Pittsburgh	Not revealed	Research
Immuno Precise	Not revealed	Research
Peter Doherty Institute for Infection and Immunity	Not revealed	Research
Tulane University	Not revealed	Research

To date, many preceding research of SARS-CoV, Middle East breathing syndrome-associated coronavirus (MERS-CoV), and different coronavirus vaccines found out numerous protection worries related to the usage of coronavirus S-primarily based totally vaccines, together with inflammatory and immunopathological results along with pulmonary eosinophilic infiltration and antibody-structured ailment enhancement (ADE) following next viral task of vaccinated animals.[65, 66, 67, 68, 69, 70, 71, 72, 73, 74]. The anti-S antibodies for ADE might also additionally facilitate uptake through macrophage expressing FcR, main to macrophage stimulation and the manufacturing of proinflammatory cytokines (IL-6, IL-8, and MCP1) and lack of tissue-repaired cytokine (TGFβ) [75]. Moreover, the Th2-related immunopathology has been documented for the inactivated vaccines of breathing syncytial virus after viral task[76, 77, 78] and the inactivated vaccines of MERS-CoV after virus task [74] Thus, the protection and the probably dangerous responses in vaccines to broaden ADE antibodies towards any coronaviruses need to be cautiously assessed in human trials [80]. It has been proposed that the neutralizing epitope-wealthy S1 region, or the RBD region, rather than the complete full-duration S protein as an opportunity goal for MERS-CoV vaccine development [81]. Whether the usage of S1 or RBD antigen of SARS-CoV-2, or the choice of Th1-skewed adjuvants instead of alum adjuvant, can keep away from the inflammatory, immunopathological, and ADE results, calls for in addition research from animal fashions and human trials. These findings are specifically essential for growing a secure and powerful COVID-19 vaccine.

The recent report says that the clinical trials for human COVID-19 vaccine have been first completed by Russia. The results have proven the medical effectiveness.

Chief researcher, who is the head of the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS about the human trials for the vaccine have been completed at the university. She also said that and they will be discharged soon.

As per the report, "The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," [94].

Moderna, a Cambridge, Massachusetts based Biotechnology company develops vaccines, which is based on the messenger RNA (mRNA) to produce viral proteins inside the body. In January, they started developing a vaccine for the coronavirus. Since then the government has provided nearly $1 billion for Moderna's effort. In partnership with National Institutes of Health, they experimented the vaccine with monkeys and found that it protects the monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine for the human trials, and it yielded promising results. The vaccine has been progressed into the Phase 3 trial and testing on July 27. [95][96]

The Oxford vaccine showed some side effects, leading to the pause in its approval. But scientists are hoping to make it's safer version to be available by the year end. [97]

Currently over 169 COVID-19 vaccine candidates are under development, among which 26 are in the human trial phase. WHO is working in collaboration with the scientists, business, and global health organizations through the ACT Accelerator to speed up with the effective pandemic response. Whenever a safe and effective vaccine will be found, COVAX (led by WHO, GAVI and CEPI) will facilitate the access and distribution of the vaccines to protect people in all over the world. People most at risk will be prioritized among others. [98]

Conclusion:

In outline, we are confronting a horrendous infection with more noteworthy infectivity than the SARS-CoV pandemic of 2003. There is directly no antibody or reported explicit enemy of SARS-CoV-2 medication routine to treat fundamentally sick patients. The vast majority of the expected medications for treatment of COVID-19 are being explored for wellbeing and adequacy against SARS-CoV-2. Remdesivir is the most encouraging specialist. Likewise, favipiravir and blend treatment with hydroxychloroquine in addition to azithromycin seem, by all accounts, to be adequate choices for treatment of COVID-19 patients. For patients with SARS-CoV-2 contamination, ACE inhibitor and ARB should be recommended with alert. Contrasted and NSAIDs, acetaminophen may be a more secure operator for rewarding fever in COVID-19 patients. At long last, low-portion steroid (hydrocortisone) may be endorsed for treatment of unmanageable stun in patients with COVID-19. And soon the vaccine will also be available in the market as the trial for some vaccines have reached for Phase 3.

Conflict of interests:

The authors of this review article declare no conflict of interest.

Acknowledgements:

We acknowledge the Amity Institute of Biotechnology, Amity University, Kolkata, India for support.

References:

1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936. doi: 10.1056/NEJMoa2001191.

2. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020;19:149–150. doi: 10.1038/d41573-020-00016-0.

3. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9 doi:10.1128/mBio.00221-18. pii: e00221-18.

4. Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. SciTransl Med. 2017;9 doi: 10.1126/scitranslmed.aal3653. pii: eaal3653.

5. Martinez M.A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9 doi: 10.1128/AAC.00399-20. pii: AAC.00399-20.

6. Warren T.K., Jordan R., Lo M.K., Ray A.S., Mackman R.L., Soloveva V. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–385.

7. Mulangu S., Dodd L.E., Davey R.T., Jr., TshianiMbaya O., Proschan M., Mukadi D. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303.

8. Medrxiv News. https://times.hinet.net/mobile/news/22831665 from.

9. Brown A.J., Won J.J., Graham R.L., Dinnon K.H., 3rd, Sims A.C., Feng J.Y. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res. 2019;169:104541.

10. Ko W.C., Rolain J.M., Lee N.Y., Chen P.L., Huang C.T., Lee P.I. Arguments

in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 Mar 6:105933. doi: 10.1016/j.ijantimicag.2020.105933.

11. de Wit E., Feldmann F., Cronin J., Jordan R., Okumura A., Thomas T. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. ProcNatlAcadSci USA. 2020 Feb 13 doi:10.1073/pnas.1922083117. pii: 201922083.

12. Chan J.F.W., Yao Y., Yeung M.L., Deng W., Bao L., Jia L. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904–1913.

13. Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–347.

14. Sheahan T.P., Sims A.C., Leist S.R., Schäfer A., Won J., Brown A.J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6.

15. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 Mar 18 doi: 10.1056/NEJMoa2001282.

16. Baden L.R., Rubin E.J. COVID-19 - the search for effective therapy. N Engl J Med. 2020 Mar 18 doi: 10.1056/NEJMe2005477.

17. News Abidol and darunavir can effectively inhibit coronavirus. http://www.sd.chinanews.com/2/2020/0205/70145.html [in Chinese]

18. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–1317.

19. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.

20. Yan Y., Zou Z., Sun Y., Li X., Xu K.F., Wei Y. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23:300–302.

21. Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.

22. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.

23. Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10 doi: 10.1016/j.jcrc.2020.03.005. pii: S0883-9441(20)30390-7.

24. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ClinInfectDis. 2020Mar9doi:10.1093/cid/ciaa237. pii:S1684-1182.

25. Gautret P., Lagier J., Parola P., Hoang V.T., Meddeb L., Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 17 doi: 10.1016/j.ijantimicag.2020.105949.

26. Madrid P.B., Panchal R.G., Warren T.K., Shurtleff A.C., Endsley A.N., Green C.E. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1:317–326.

27. Bacharier L.B., Guilbert T.W., Mauger D.T., Boehmer S., Beigelman A., Fitzpatrick A.M. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314:2034–2044.

28. Wang Y., Cui R., Li G., Gao Q., Yuan S., Altmeyer R. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antivir Res. 2016;125:1–7. doi: 10.1016/j.antiviral.2015.11.003.

29. Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) J Biol Chem. 2016;291:9218–9232.

30. Baron S.A., Devaux C., Colson P., Raoult D., Rolain J.M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020 Mar 13:105944. doi: 10.1016/j.ijantimicag.2020.105944.

31. Beigel J.H., Nam H.H., Adams P.L., Krafft A., Ince W.L., El-Kamary S.S. Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference. Antivir Res. 2019;167:45–67. doi: 10.1016/j.antiviral.2019.04.006.

32. Beigel J.H., Voell J., Kumar P., Raviprakash K., Wu H., Jiao J.A. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18:410–418.

33. Cockrell A.S., Yount B.L., Scobey T., Jensen K., Douglas M., Beall A. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016;2:16226.

34. Glowacka I., Bertram S., Müller M.A., Allen P., Soilleux E., Pfefferle S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85:4122–4134.

35. Kawase M., Shirato K., van der Hoek L., Taguchi F., Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537–6545.

36. Zhou Y., Vedantham P., Lu K., Agudelo J., Carrion R., Jr., Nunneley J.W. Protease inhibitors targeting coronavirus and filovirus entry. Antivir Res. 2015;116:76–84.

37. News FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients. https://www.pharmaceutical-business-review.com/news/covacta-trial- actemra-covid-19/

38. Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 S1473–3099(20)30141-30149.

39. Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Mar 27 doi: 10.1001/jama.2020.4783.

40. Cunningham A.C., Goh H.P., Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24:91.

41. Luo H., Tang Q.L., Shang Y.X., Liang S.B., Yang M., Robinson N. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020 Feb 22 doi: 10.1007/s11655-020-3192-6.

42. Lai CC, Wang CY, HsuehPR.Co-infection among patients with COVID-19.

43. Chou C.C., Shen C.F., Chen S.J., Chen H.M., Wang Y.C., Chang W.S.

Recommendations and guidelines for the treatment of pneumonia in Taiwan. J MicrobiolImmunol Infect. 2019;52:172–199. doi: 10.1016/j.jmii.2018.11.004.

44. Jean S.S., Chang Y.C., Lin W.C., Lee W.S., Hsueh P.R., Hsu C.W. Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. J Clin Med. 2020;9:275. doi: 10.3390/jcm9010275.

45. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24 doi: 10.1016/S2213-2600(20)30079-5.

46. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28 doi: 10.1056/NEJMoa2002032.

47. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Mar 11 doi: 10.1016/S2213-2600(20)30116-8.

48. FDA News No scientific evidence that NSAID use worsens COVID-19 symptoms.https://www.drugtopics.com/latest/fda-no-scientific-evidence-nsaid- use-worsens-covid-19-symptoms

49. Day M. COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020 Mar 17;368:m1086. doi: 10.1136/bmj.m1086.

50. Society of Critical Care Medicine COVID-19 Guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19

51. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13 doi: 10.1001/jamainternmed.2020.0994.

52. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost. 2020 March 27 doi: 10.1111/jth.14817.

53. Wösten-van Asperen R.M., Bos A.P., Bem R.A., Dierdorp B.S., Dekker T., van Goor H. Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. PediatrCrit Care Med. 2013;14:e438–e441. doi: 10.1097/PCC.0b013e3182a55735.

54. Fedson D.S. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4:421. doi: 10.21037/atm.2016.11.03.

55. Fedson D.S., Opal S.M., Rordam O.M. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11 doi: 10.1128/mBio.00398-20.

56. Mistraletti G., Umbrello M., Sabbatini G., Miori S., Taverna M., Cerri B., Mantovani E.S., Formenti P., Spanu P., D'Agostino A., Salini S., Morabito A., Fraschini F., Reiter R.J., Iapichino G. Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial. Minerva Anestesiol. 2015;81:1298–1310.

57. Andersen L.P.H., Gogenur I., Rosenberg J., Reiter R.J. The safety of melatonin in humans. Clin. Drug Investig. 2016;36:169–175. doi: 10.1007/s40261-015-0368-5.

58. Bourne R.S., Mills G.H., Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit. Care (London, England). 2008;12:R52. doi: 10.1186/cc6871.

59. Mistraletti G., Sabbatini G., Taverna M., Figini M.A., Umbrello M., Magni P., Ruscica M., Dozio E., Esposti R., DeMartini G., Fraschini F., Rezzani R., Reiter R.J., Iapichino G. Pharmacokinetics of orally administered melatonin in critically ill patients. J. Pineal Res. 2010;48:142–147. doi: 10.1111/j.1600-079X.2009.00737.x.

60. Nordlund J.J., Lerner A.B. The effects of oral melatonin on skin color and on the release of pituitary hormones. J. Clin. Endocrinol. Metab. 1977;45:768–774. doi: 10.1210/jcem-45-4-768.

61. Sun C.-K., Lee F.-Y., Kao Y.-H., Chiang H.-J., Sung P.-H., Tsai T.-H., Lin Y.-C., Leu S., Wu Y.-C., Lu H.-I., Chen Y.-L., Chung S.-Y., Su H.-L., Yip H.-K. Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. J. Pineal Res. 2015;58:137–150. doi: 10.1111/jpi.12199.

62. Reiter R.J., Ma Q., Sharma R. Treatment of Ebola and other infectious diseases: melatonin "goes viral" Melatonin Res. 2020;3:43–57. doi: 10.32794/mr11250047.

63. Wu X., Ji H., Wang Y., Gu C., Gu W., Hu L., Zhu L. Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 axis. Oxidative Med. Cell. Longev. 2019;2019:4087298. doi: 10.1155/2019/4087298.

64. Lv C., Liu W., Wang B. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 2018;159:55–62.

65. Weiss R. C., Scott F. W., Comp. Immunol.,Microbiol. Infect. Dis. 1981, 4, 175.

11. Olsen C. W., Corapi W. V., Ngichabe C. K., Baines J. D., Scott F. W., J. Virol. 1992, 66, 956.

66. He Y., Zhou Y., Wu H., Luo B., Chen J., Jiang S., J. Immunol. 2004, 173, 4050.

67. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., Smith G., Jones S., Proulx R., Deschambault Y., Grudeski E., Andonov A., He R., Li Y., Copps J., Grolla A., Dick D., Berry J., Ganske S., Manning L., Cao J., J. Virol. 2004, 78, 12672.

68. Czub M., Weingartl H., Czub S., He R., Cao J., Vaccine 2005, 23, 2273.

69. Yang Z. Y., Werner H. C., Kong W. P., Leung K., Traggiai E., Lanzavecchia A., Nabel G. J., Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 797.

70. Deming D., Sheahan T., Heise M., Yount B., Davis N., Sims A., Suthar M., Harkema J., Whitmore A., Pickles R., West A., Donaldson E., Curtis K., Johnston R., Baric R., PLoS Med. 2006, 3, e525.

71. Kam Y. W., Kien F., Roberts A., Cheung Y. C., Lamirande E. W., Vogel L., Chu S. L., Tse J., Guarner J., Zaki S. R., Subbarao K., Peiris M., Nal B., Altmeyer R., Vaccine 2007, 25, 729.

72. Jaume M., Yip M. S., Kam Y. W., Cheung C. Y., Kien F., Roberts A., Li P. H., Dutry I., Escriou N., Daeron M., Bruzzone R., Subbarao K., Peiris J. S., Nal B., Altmeyer R., Hong Kong Med. J. 2012, 18, 31.

73. Tseng C. T., Sbrana E., Iwata-Yoshikawa N., Newman P. C., Garron T., Atmar R. L., Peters C. J., Couch R. B., PLoS One 2012, 7, e35421.

74. Agrawal A. S., Tao X., Algaissi A., Garron T., Narayanan K., Peng B. H., B. Couch R., Tseng C.-T. K., Hum. Vaccines Immunother. 2016, 12, 2351.

75. Liu L., Wei Q., Lin Q., Fang J., Wang H., Kwok H., Tang H., Nishiura K., Peng J., Tan Z., Wu T., Cheung K. W., Chan K. H., Alvarez X., Qin C., Lackner A., Perlman S., Yuen K. Y., Chen Z., JCI Insight 2019, 4, e123158.

76. Johnson T. R., Parker R. A., Johnson J. E., Graham B. S., J. Immunol. 2003, 170, 2037.

77. Kapikian A. Z., Mitchell R. H., Chanock R. M., Shvedoff R. A., Stewart C. E., Am. J. Epidemiol. 1969, 89, 405.

78. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H., Am. J. Epidemiol. 1969, 89, 422.

79. Jiang S., Nature 2020, 579, 321.

80. Hashem A. M., Algaissi A., Agrawal A. S., Al-Amri S. S., Alhabbab R. Y., Sohrab S. S., Almasoud A. S., Alharbi N. K., Peng B. H., Russel M., Li X., Tseng, C. K., J. Infect. Dis. 2019, 220, 1558.

81.https://www.Raps.Org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker? Feed=Regulatory-Focus? Utm_source=Facebook&utm_medium=social&utm_campaign=Regulatory-Focus.

82. Progress and Concept for COVID-19 Vaccine DevelopmentSuh-Chin Wu.

83."WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China". www.who.int. 2020-01-09. Archived from the original on 2020-01-14. Retrieved 2020-01-10.

84. "Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection. Interim guidance, 10 January 2020" (PDF). Archived (PDF) from the original on 2020-01-20. Retrieved 2020-01-14.

85. "Novel Coronavirus 2019, Wuhan, China". www.cdc.gov (CDC). 2020-01-23. Archived from the original on 2020-01-20. Retrieved 2020-01-23.

86. "2019 Novel Coronavirus infection (Wuhan, China): Outbreak update". Canada.ca. 2020-01-21.

87. Wang Y., Fan G., Salam A., Horby P., Hayden F.G., Chen C. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivirmonotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2019 Dec 11 doi: 10.1093/infdis/jiz656. pii: jiz656. 88. Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. ProcJpnAcadSer B PhysBiol Sci. 2017;93:449–463.

89. XinhuaNetFavipiravir shows good clinical efficacy in treating COVID-19: official. From. http://www.xinhuanet.com/english/2020-03/17/c_138888226.htm

90. World Health Organization. Situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 22 Feb 2020.

91. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020 Feb 6.pii: S0195–6701(20)30046–3.

92. Richman DD, Whitley RJ, Hayden FG. Clinical Virology, 4th ed. Washington: ASM Press; 2016.

93. https://cepi.Net/covid-19/

94.https://health.economictimes.indiatimes.com/news/industry/russia-1st-nation-to-finish-human-trials-for-covid-19-vaccine/76938659

95. https://en.wikipedia.org/wiki/Moderna

96.https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html#:~:text=In%20partnership%20with%20National%20Institutes,which%20began%20on%20July%2027.

97.https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-vaccine-update-oxford-vaccine-can-still-be-ready-by-year-end-says-astrazeneca-ceo/photostory/78061608.cms 98. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines?gclid=CjwKCAjw4_H6BRALEiwAvgfzq27_qlz0mh-5WUHGVBa0opiFzhqNvYt30x6kU-gSngCXePrS9Qe8WxoCbyUQAvD_BwE.